首页> 外文期刊>Journal of clinical laboratory analysis. >Identification of Novel Low Molecular Weight Serum Peptidome Biomarkers for Non‐Small Cell Lung Cancer (NSCLC)
【24h】

Identification of Novel Low Molecular Weight Serum Peptidome Biomarkers for Non‐Small Cell Lung Cancer (NSCLC)

机译:非小细胞肺癌(NSCLC)的新型低分子量血清肽组生物标志物的鉴定

获取原文
           

摘要

To identify discriminating protein patterns in serum samples among non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), pneumonia, and healthy controls. To discover specific low molecular weight (LMW) serum peptidome biomarkers and establish a diagnostic pattern for NSCLCby using proteomic technology.MethodsWe used magnetic bead-based separation followed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) to identify patients with NSCLC, COPD, and pneumonia. A total of 154 serum samples were analyzed in this study, among which there were 60 serum samples from NSCLC patients, 30 from patients with other lung-related diseases (16 pneumonia patients and 14 patients with COPD) as disease controls, and 64 from healthy volunteers as healthy control. The mass spectra, analyzed using ClinProTools software, distinguished between cancer patients and healthy individuals based on GA algorithm model.ResultsIn this study, we generated numerous discriminating m/z peaks as well as disease-specific discrimination peaks. A set of five potential biomarkers (m/z: 7,763.24, 1,012.61, 4,153.16, 1,450.55, and 2,878.89) could be used as the diagnostic biomarkers to distinguish NSCLCpatients from healthy controls. In the training set, patients with NSCLC could be identified with sensitivity of 97.5% and specificity of 98.8%. Similar results were obtained in the testing set, showing 80.7% sensitivity and 91.2% specificity.ConclusionOur study demonstrated that a combined application of magnetic beads with MALDI-TOF MS technique was suitable for identification of serum biomarkers for NSCLC. J. Clin. Lab. Anal. 26:148-154, 2012. ? 2012 Wiley Periodicals, Inc.
机译:为了在非小细胞肺癌(NSCLC),慢性阻塞性肺疾病(COPD),肺炎和健康对照人群中鉴定血清样品中的区别蛋白模式。通过蛋白质组学技术来发现特定的低分子量(LMW)血清肽组生物标志物并建立NSCLC的诊断模式。方法我们使用基于磁珠的分离,然后进行基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS) )以识别患有NSCLC,COPD和肺炎的患者。本研究共分析了154份血清样本,其中60份来自NSCLC患者的血清样本,30份来自其他肺相关疾病的患者(16例肺炎患者和14例COPD患者)作为疾病对照,而64份来自健康人群志愿者作为健康对照。使用ClinProTools软件分析的质谱图基于GA算法模型区分癌症患者和健康个体。结果在这项研究中,我们生成了许多可区分的m / z峰以及特定疾病的鉴别峰。可以使用一组五个潜在的生物标记物(m / z:7,763.24、1,012.61、4,153.16、1,450.55和2,878.89)作为诊断生物标记物,以区分非小细胞肺癌患者与健康对照。在训练中,NSCLC患者的敏感度为97.5%,特异性为98.8%。在测试组中获得了相似的结果,显示出80.7%的灵敏度和91.2%的特异性。结论我们的研究表明,磁珠与MALDI-TOF MS技术的组合应用适合鉴定NSCLC的血清生物标志物。 J.临床。实验室肛门26:148-154,2012。 2012 Wiley期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号